TRV
Same song, different verse
BMO Capital is sticking with Outperform on Travelers (TRV), which is analyst-speak for: we still like the stock, don’t panic yet. The firm says expectations for Travelers may keep drifting higher as Wall Street folds in first-quarter 2026 reserve releases.
The catch: pricing is cooling
That’s the good news, but there’s a little asterisk attached. BMO also expects commercial insurance pricing growth to slow, which could nudge Travelers’ underlying loss ratio higher. In plain English: the company may be making less easy money on pricing power, even if the earnings math still looks sturdy.
Wall Street’s little tug-of-war
The broader analyst chatter around Travelers is basically a group chat in disagreement:
- Evercore ISI recently raised its price target and kept an Outperform rating, pointing to buyback potential.
- BofA Securities lifted its target too, but kept an Underperform rating — because apparently even a nicer price target can come with a side-eye.
For investors, the key question is whether Travelers’ Q1 strength is the start of a longer run or just a nice weather day in an otherwise more competitive insurance market.
Big picture: Travelers still has believers, but the market is now watching whether reserve releases can keep offsetting a slower pricing backdrop without squeezing profitability.